The 14th Annual Pharmacogenetics in Psychiatry Meeting
October 15, 2015
Omni King Edward Hotel, Toronto, Canada

Thursday, October 15, 2015

7:30 AM    Continental Breakfast
8:15 AM    Welcome and Introduction

SESSION I: PHARMACOGENETICS OF CLOZAPINE RESPONSE
Chair: Anil K. Malhotra

8:30 AM    Establishing the Characteristics of an Effective Pharmacogenetics Test for Clozapine Induced Agranulocytosis
Moira Verbelen
King’s College, London, UK

8:55 AM    An Epigenome-wide Association Study of Clozapine Use in Treatment-resistant Schizophrenia
Eilís Hanlon
University of Exeter, England, UK

9:20 AM    Neurobiological Correlates of Clozapine Response in Patient-derived Neurons
Rakesh Karmacharya
Harvard University, Massachusetts, USA

9:45 AM    Break

SESSION II: PHARMACOGENETICS OF ANTIPSYCHOTIC DRUGS
Chair: James Kennedy

10:00 AM Complex Genetic Overlap Between Schizophrenia Risk and Antipsychotic Response
Douglas Ruderfer
Icahn School of Medicine at Mount Sinai, New York, USA

10:25 AM Investigating the Functional Significance of Genome-wide Variants Associated with Antipsychotic Treatment Response
Ellen Ovenden
Stellenbosch University, South Africa, Africa

10:50 AM Schizophrenia risk variant at DRD2 locus predicts antipsychotic treatment response in first episode psychosis
Jianping Zhang
The Zucker Hillside Hospital, New York, USA

11:15 AM Preliminary Evidence for Association of Genome-wide Significant DRD2 Schizophrenia Risk Variant with Clozapine Response
Eric Huang
11:40 AM  *Pharmacogenetics of Antipsychotic-induced Weight Gain in Multiple Drug-naïve Cohorts*
Todd Lencz
The Zucker Hillside Hospital, New York, USA

12:05 PM  Lunch on Own

**SESSION III: PHARMACOGENETICS OF MOOD & ANXIETY DISORDERS**
*Chair: David Goldman*

1:30 PM  *Epigenetics in Anxiety Disorders*
Katharina Domschke
University of Würzburg, Germany

1:55 PM  *Common Genetic Markers for Lithium Response in Bipolar Disorder*
Francis J. McMahon
National Institute of Mental Health Intramural Research Program, Maryland, USA

2:20 PM  *Genetics of Long-term Treatment Outcome in Bipolar Disorder*
Alessandro Serretti
University of Bologna, Italy

2:45 PM  *Genome-wide Association Analyses in Clinical Response to Duloxetine and Placebo in Major Depression*
Daniel Müller
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

3:10 PM  *Genome-wide Association Study of Lithium Response in a Prospective Trial Sample - The Pharmacogenomics of Bipolar Disorder Study*
John Kelsoe
University of California, San Diego, California, USA

3:35 PM  Break

**SESSION IV: THE CRESTAR CONSORTIUM: DEVELOPMENT OF BIOMARKERS FOR SCHIZOPHRENIA**
*Chair: David A. Collier*
*Co-Chair: Dan Rujescu*

3:45 PM  *The CRESTAR Consortium: Overview*
David A. Collier
Eli Lilly and Company, LTD

4:00 PM  *Pharmacogenomics of Agranulocytosis*
Dan Rujescu
Martin-Luther-University Halle-Wittenberg
4:20 PM  \textit{Genomics of Treatment-resistant Schizophrenia}
Sophie Legge
MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University

4:45 PM  \textit{Predicting Models Within Pharmacogenomics}
Cathryn Lewis, Ph.D.
King’s College London

5:10 PM  Meeting Adjourns

5:30 PM  Poster Session and Reception